person · Reporting owner

CARDOZA GEORGE

Disclosed activity across 2 companies

Tapewire entity: 31643
SEC CIK: 0001518734

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
NEOGENOMICS INCNEO · Entity 2096	President & COO, Lab Ops	March 01, 2022	March 04, 2022
SOPHiA GENETICS SASOPH · Entity 5228	Chief Financial Officer	October 05, 2026	October 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NEOGENOMICS INC

Report date March 01, 2022 · Filed March 04, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	244,157	Ending reported balance After 2022-03-02 transaction · row 3 2 source rows · reconciled sequence Row 2 · 2022-03-01 · Tax withholding · Disposed 503 · Balance 244,996 F1: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2022 vesting of restricted stock. Row 3 · 2022-03-02 · Tax withholding · Disposed 839 · Balance 244,157 F2: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2022 vesting of restricted stock.
Common StockSEC Table I · non-derivative	IndirectTrust by Self	20,000	Reported balance Holding disclosure · report date 2022-03-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 20,000
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.52 · Expires 2022-04-28	Direct	50,000	Reported balance Holding disclosure · report date 2022-03-01 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 50,000 F3: On April 28, 2017, Mr. Cardoza was granted 200,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.03 · Expires 2023-02-26	Direct	192,500	Reported balance Holding disclosure · report date 2022-03-01 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 192,500 F4: On February 26, 2018, Mr. Cardoza was granted 192,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.60 · Expires 2024-03-01	Direct	51,459	Reported balance Holding disclosure · report date 2022-03-01 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 51,459 F5: On March 1, 2019, Mr. Cardoza was granted 51,459 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.33 · Expires 2027-03-02	Direct	48,768	Reported balance Holding disclosure · report date 2022-03-01 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 48,768 F6: On March 2, 2020, Mr. Cardoza was granted 48,768 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.17 · Expires 2028-03-02	Direct	35,171	Reported balance Holding disclosure · report date 2022-03-01 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 35,171 F7: On March 2, 2021, Mr. Cardoza was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.95 · Expires 2028-07-05	Direct	40,502	Reported balance Holding disclosure · report date 2022-03-01 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance 40,502 F8: On July 5, 2021, Mr. Cardoza was granted 40,502 stock options. These options vest ratably over the first four anniversary dates of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2022 vesting of restricted stock.

F2: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2022 vesting of restricted stock.

F3: On April 28, 2017, Mr. Cardoza was granted 200,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.

F4: On February 26, 2018, Mr. Cardoza was granted 192,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.

F5: On March 1, 2019, Mr. Cardoza was granted 51,459 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F6: On March 2, 2020, Mr. Cardoza was granted 48,768 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F7: On March 2, 2021, Mr. Cardoza was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F8: On July 5, 2021, Mr. Cardoza was granted 40,502 stock options. These options vest ratably over the first four anniversary dates of the grant date.

SOPHiA GENETICS SA

Report date October 05, 2026 · Filed October 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	306,726	Reported balance After 2026-10-05 transaction · row 1 1 source row Row 1 · 2026-10-05 · Sale · Disposed 1,592 · Balance 306,726 F1: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 2, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.23, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on October 2, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.23, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 25, 2017 Filed May 30, 2017 21:07 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantRestricted Stock · Derivative	25,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-17-036157 · doc4.xml · derivative · entry 7 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F5 · security: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F6 · derivative.exercise_date: Restricted stock will vest as follows; 8,333 units will vest on May 25, 2018 and 2019 and 8,334 units will vest on May 25, 2020. F7 · derivative.expiration_date: These restricted stock units will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document
April 28, 2017 Filed May 2, 2017 20:35 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantStock Option (Right to Buy) · Derivative	200,000	$7.52 Strike: $7.52	$1,504,000.00	Disclosure SEC source: 0001209191-17-029213 · doc4.xml · derivative · entry 6 CARDOZA GEORGE · CIK 0001518734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-04-28 F4 · derivative.exercise_date: On April 28, 2017, Mr. Cardoza was granted 200,000 stock options. These options vest ratably over the next three anniversary dates of the grant date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.